Trial Profile
A PHASE 2A, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF-06651600 AND PF-06700841 AS INDUCTION AND OPEN LABEL EXTENSION TREATMENT IN SUBJECTS WITH MODERATE TO SEVERE CROHN'S DISEASE
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Brepocitinib (Primary) ; Ritlecitinib (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 30 Oct 2023 Status changed from active, no longer recruiting to completed.
- 13 Oct 2023 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 16 Jul 2023 This trial has been completed in Germany, according to European Clinical Trials Database record.